Resection of primary lesion for patients with metastatic breast cancer: where are we now?

被引:6
|
作者
Hu, Qiancheng [1 ]
Zhong, Xiaorong [1 ,2 ,3 ]
Liu, Xu [2 ]
Xie, Yuxin [1 ,2 ]
Hu, Kejia [2 ]
He, Ping [1 ,3 ]
Lu, Donghao [1 ,3 ,4 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Med Sch, West China Hosp, Dept Med Oncol,Canc Ctr, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Med Sch, West China Hosp,Natl Collaborat Innovat Ctr Bioth, State Key Lab Biotherapy,Lab Tumor Mol Diag, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Chengdu 610041, Sichuan, Peoples R China
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
基金
中国国家自然科学基金;
关键词
Breast cancer; distant metastasis; resection of the primary lesion;
D O I
10.21037/cco.2018.05.03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is largely unclear that whether or not surgical resection of the primary tumors could confer survival benefit among patients with metastatic breast cancer at initial presentation. We thoroughly reviewed the up-to-date evidence on surgical resection of the primary lesion in metastatic breast cancer, including comparative studies (of particular interest in risk modifiers, the type, and timing of surgical procedures), Chinese and international guidelines, as well as the progress of clinical trials. Partial modified radical mastectomy and breast-conserving surgery are by far the most common choices for patients with metastatic breast cancer. Patients with certain characteristics, for example, younger than 45 years of age or with oligometastasis, might benefit from the surgery. The type and timing of surgical procedures are still in debate according to the guidelines from different countries. Forthcoming evidence from the ongoing clinical trials might help close the knowledge gaps in surgical treatment for patients with metastatic breast cancer and aid the decision-making in clinical practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Adjuvant chemotherapy in elderly patients with breast cancer: where are we?
    Wildiers, H
    Brain, EGC
    CURRENT OPINION IN ONCOLOGY, 2005, 17 (06) : 566 - 572
  • [22] Breast cancer research: where we are and where we should go
    Edison T Liu
    Breast Cancer Research, 2
  • [23] Pulmonary resection for metastatic breast cancer
    Simpson, R
    Kennedy, C
    Carmalt, H
    McCaughan, B
    Gillett, D
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1997, 67 (10): : 717 - 719
  • [24] Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis
    Ruiterkamp, J.
    Ernst, M. F.
    van de Poll-Franse, L. V.
    Bosscha, K.
    Tjan-Heijnen, V. C. G.
    Voogd, A. C.
    EJSO, 2009, 35 (11): : 1146 - 1151
  • [25] Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
    Schettini, Francesco
    Buono, Giuseppe
    Cardalesi, Cinzia
    Desideri, Isacco
    De Placido, Sabino
    Del Mastro, Lucia
    CANCER TREATMENT REVIEWS, 2016, 46 : 20 - 26
  • [26] Primary systemic therapy on local advance breast cancer, where are we going?
    Cinieri, S.
    Orlando, L.
    Colleoni, M.
    ANNALS OF ONCOLOGY, 2006, 17 : VII18 - VII21
  • [27] Hepatic Resection for Metastatic Breast Cancer: Prognostic Analysis of 34 Patients
    Yoshihiro Sakamoto
    Junji Yamamoto
    Masataka Yoshimoto
    Fujio Kasumi
    Tomoo Kosuge
    Norihiro Kokudo
    Masatoshi Makuuchi
    World Journal of Surgery, 2005, 29 : 524 - 527
  • [28] Breast Cancer Survivorship: Where Are We Today?
    Ganz, Patricia A.
    Goodwin, Pamela J.
    IMPROVING OUTCOMES FOR BREAST CANCER SURVIVORS: PERSPECTIVES ON RESEARCH CHALLENGES AND OPPORTUNITIES, 2015, 862 : 1 - 8
  • [29] Breast Cancer in India: Where Do We Stand and Where Do We Go?
    Khokhar, Anita
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 4861 - 4866
  • [30] Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
    Force, Jeremy
    Santos Leal, Jorge Henrique
    McArthur, Heather L.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (04)